# Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

> **NCT04217629** · PHASE1 · COMPLETED · sponsor: **Suzhou Yabao Pharmaceutical R&D Co., Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** SY-005

## Key facts

- **NCT ID:** NCT04217629
- **Lead sponsor:** Suzhou Yabao Pharmaceutical R&D Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-26
- **Primary completion:** 2019-10-05
- **Final completion:** 2020-08-19
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04217629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04217629, "Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04217629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*